Sid Roychoudhury, PhD

Sid Roychoudhury is a Program Strategy Leader at Gilead Sciences where he leads multiple immuno-oncology programs in clinical development, including monoclonal antibodies targeting TIGIT and small molecules targeting the immune-suppressive adenosine axis in the tumor microenvironment. These programs are being developed for multiple solid tumors in partnership with Arcus Biosciences. Prior to joining Gilead in 2021, Sid was a Global Product General Manager at Amgen where he led 10+ development programs including bispecific and bifunctional biologics, novel protein scaffolds, and monoclonal antibodies in Oncology and Inflammation therapeutic areas through key milestones, such as first-in-human, early-to-late clinical phase transition, and commitment to registrational studies. Prior to joining Amgen in 2015, Sid spent ~12 years at Janssen R&D in various positions of increasing responsibilities in medical affairs, project management, external innovation, and finally as a Compound Development Team Leader within the Immunology therapeutic area. Sid spent ~ 8 years in anti-bacterial drug discovery at Procter & Gamble Pharmaceuticals and led the discovery of TAIGEXYN®, a non-fluorinated quinolone, which is approved in multiple countries for the treatment of drug-resistant infections. Sid conducted his postdoctoral research at Eli Lilly & Company and holds a PhD in microbiology & immunology from University of Illinois College of Medicine in Chicago.
Speaking In
1:45 PM - 2:45 PM (PDT)
Tuesday, June 14
Given a less than 8% likelihood for a New Drug Approval from first in man clinical trials, drug…